This editorial refers to 'Whole human heart histology to validate electroanatomical voltage mapping in patients with non-ischaemic cardiomyopathy and ventricular tachycardia' † , by C.A. Glashan et al., on page 2867.
This editorial refers to 'Whole human heart histology to validate electroanatomical voltage mapping in patients with non-ischaemic cardiomyopathy and ventricular tachycardia' † , by C.A. Glashan et al., on page 2867.
For more than two decades, electroanatomical voltage mapping (EAVM) using various three-dimensional (3D) mapping systems has constituted a diagnostic and therapeutic cornerstone for mapping and ablating ventricular tachycardia (VT) in patients with structural heart disease. 1 Previous work has shown that EAVM can be regarded as a very helpful tool for the clinical cardiac electrophysiologist to detect pathological fibrous, fatty, or inflammatory infiltrates inside the myocardium, leading to annotation of low voltage areas or dense scar in 3D maps, which facilitates mapping and catheter ablation of different cardiac arrhythmias including macro-reentrant VT, and can significantly reduce procedure and fluoroscopy times. 2 Important questions arise while trying to understand the pathological substrate during EAVM. They refer to cut-off levels of bipolar and unipolar voltage maps, what to consider abnormal, and what to do if EAVM cannot be performed during sinus rhythm, since traditionally reference values have been obtained during sinus rhythm, whereas different rhythms can significantly alter voltage values. With regard to this, several studies at the beginning of this millennium have suggested different cut-off levels for normal and abnormal bipolar and unipolar, endocardial and epicardial, right ventricular and left ventricular voltages that are obtained by 3D EAVM. In current practice worldwide, based on these previously proposed cut-off values to detect fibrosis and other forms of a pathological substrate, low voltage areas are often defined as reproducible electrograms with a bipolar voltage (BV) <1.5 mV or unipolar voltage (UV) of <8.27 mV for the LV endocardium, and BV <1.0-1.5 mV and UV <7.95 mV for the epicardium. [3] [4] [5] Of note, evidence for these cut-off values in humans has been derived from either animal studies of myocardial infarction or non-randomized small observational studies in <10 control probands who were predominantly male and younger as compared with those who suffered from substrate-based VT. Furthermore, cut-off points were set if 95% of all electrogram signals recorded were above this threshold, e.g. 1.5 mV for endocardial BV. From a statistical point of view, this method is problematic, since values have been derived from small populations, and it assumes independence of individual voltage values from one another and does not consider repeated measurements in the same individual. 6 Accordingly, the cut-off for dense scar has been somewhat arbitrarily set to BV <0.5 mV based on studies of catheter ablation and cardiac surgery for ischaemic scar-related VT. 3 In this context, in this issue of the journal, Glashan et al. 7 analysed for the first time EAVM for pathological substrate delineation in nonischaemic cardiomyopathy (NICM) and validated their findings from EAVM by full human heart histology obtained at autopsy or transplantation. The authors conclude that a pathological substrate in NICM is fundamentally different from that in ischaemic cardiomyopathy, and the approach to EAVM (BV and UV) currently applied worldwide needs to be redefined and take the amount and type of fibrosis, and of particular importance myocardial wall thickness, into account. This is certainly a small observational single-centre study investigating eight male patients (median age 63 years) with sustained monomorphic VT due to NICM being referred for EAVM and catheter ablation to a tertiary care centre. However, this study validates findings from endocardial and epicardial EAVM by whole human heart histology, is well conducted, the findings are novel, and therefore it has a great potential to change daily clinical practice in cardiac electrophysiology. The authors have to be particularly congratulated for an excellent collaboration between their cardiac electrophysiology team, basic scientists, radiologists, pathologists, anatomists, statisticians, and biotechnicians without whom this innovative work using an in-house-developed software to trace cardiac contours onto the images of the anatomical short-axis slices, creating 3D meshes from these contours, importing them into the 3D mapping system, and merging with EAVM data would probably not have been possible. It is important to mention that conclusions derived from this study only apply to patients with sustained monomorphic VT in NICM and left ventricular measurements, whereas right ventricular measurements have not been assessed, and patients with ischaemic cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, non-compaction cardiomyopathy, and cardiac sarcoidosis were excluded. Since only male patients were recruited, the applicability of the conclusions to females remains to be demonstrated.
Nevertheless, this study is the first to provide detailed histological data on fibrosis in NICM patients with sustained monomorphic VT and to link information from left ventricular EAVM with histology, which is considered the gold standard for fibrosis identification. An interesting additional finding is that the fibrosis pattern in NICM is highly variable and not restricted to the mid-wall and subepicardium. The fibrosis architecture in NICM seems to be often patchy or diffuse, whereas the compact fibrosis architecture observed in infarct scar is very rare in NICM. This may cause underdetection of fibrosis by current cardiac magnetic resonance imaging techniques, as shown by the authors in a single patient. With regard to this, it is worth mentioning that fibrosis imaging-based VT ablation has been shown to yield better ablation outcomes than conventional ablation. 8 Therefore, it is possible to speculate that with improved tools for fibrosis imaging in the future, outcomes of VT ablation can be improved further. Other very important observations comprise a positive linear relationship between left ventricular wall thicknesswhich was determined ex vivo in the formalin-preserved heart-the amount of viable myocardium, UV, and, contrary to the general notion, BV as well. It is also interesting to note that contrary to most commonly held beliefs, BV is not restricted by a near 'field of view'. With regard to this, almost one-third of transmural biopsies generating BV < _1.5 mV showed a mid-wall or subepicardial fibrosis pattern without subendocardial involvement.
Probably the most important two findings of the study by Glashan et al., which can significantly affect future research and clinical practice, are first, that single voltage cut-offs to detect fibrosis, as currently applied in daily practice, cannot be valid considering the broad range of different wall thicknesses, viable myocardium, and other factors such as contact force, catheter design, and catheter orientation. Accordingly, different fixed cut-off levels for determining the amount of fibrosis in this study performed poorly, with areas under the curve between 0.66 and 0.72. Secondly, as the relationship between voltage amplitudes and wall thickness remains linear with increasing fibrosis, it may be possible to determine the amount of fibrosis if the local wall thickness is known. Related to this latter aspect, the authors have derived two separate mathematical equations for BV and UV, which accommodate these considerations: %fibrosis = 78:17 ðabsolute term 1Þ þ 4:67 ðabsolute term 2Þ ðex vivo wall thicknessÞ -16:67ðabsolute term 3Þðunipolar voltageÞ %fibrosis = 44 ðabsolute term 1Þ þ 3:6 ðabsolute term 2Þ ðex vivo wall thicknessÞ -20 ðabsolute term 3Þ ðbipolar voltageÞ Since this was a small study, the results certainly need validation in larger prospective cohorts using in vivo wall thickness and fibrosis assessment, including other cardiomyopathies and women. Another potential limitation is the lack of information on contact force, and it is likely that a higher contact force is associated with a higher voltage. 9 Other limitations include the inherent inaccuracies associated with merging the post-mortem data with the in vivo EAVM data, and the time between the interventions (mapping and ex vivo data). The latter is less likely to be of concern as the scar pattern and the EAVM are less likely to change significantly within months. Nevertheless, this study highlights the complex patterns of scar in NICM, which appears to defy existing algorithms to predict scar based on voltage criteria. The authors rightfully point out that smaller interelectrode spacing might avoid far field contamination and provide a true representation of the surface being mapped. At the same time, mid-wall scar may be missed by this approach. High-density mapping catheters with the capability of providing near field and far field voltages by clever computation of voltage between the electrodes might solve this problem, but this remains to be seen. In summary, this interesting and innovative study concludes that the approach to EAVM currently applied worldwide needs to be redefined and should include the amount and type of myocardial fibrosis, and, of particular importance, should take myocardial wall thickness into account. The authors provide a tool to meet this need, which may help to improve the currently modest outcomes of catheter ablation of sustained VT in patients with NICM in the future. Time will tell whether this study will initiate a change in current clinical practice of 'one size fits all' for voltage cut-off values during EAVM. It should be mentioned that even although there are 'fixed' cut-off values for EAVM, many operators 'play' with these cut-off values in order to better delineate the pathological substrate and to identify crucial myocardial channels to guide catheter ablation of VT (Take home figure) .
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